Acute Herpes Zoster:
Conditions
Interventions
The experimental group:Paravertebral nerve block was carried out using bupivacaine liposome injection
The control group:Paravertebral nerve block was performed using bupivacaine hydrochloride
Sponsors
Affiliated Hospital of Guangdong Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 years or above; 2. Meets diagnostic criteria for postherpetic neuralgia: history of herpes zoster, presenting with needle-prick, electric shock-like, or burning pain in the corresponding nerve distribution area; localised hyperalgesia, hyperesthesia, or numbness may be present, with possible herpetic lesions or residual hyperpigmentation; 3. Lesion location within the C2–C7 or T1–L5 spinal nerve distribution areas; 4. Visual analogue scale (VAS) score > 3 points; 5. Diagnosis of postherpetic neuralgia within one month of herpes eruption, with prior standard antiviral treatment; 6. No immunomodulatory agents taken within the preceding four weeks; 7. Willingness to comply with treatment and follow-up protocols; 8. Signed informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients with bacterial infection at the site of skin lesions; 2. Patients with severely compromised immune function or those undergoing long-term corticosteroid or immunosuppressive therapy; 3. Patients with severe organ dysfunction; 4. Patients with severe coagulation disorders; 5. Patients with known hypersensitivity to the investigational medicinal product; 6. Pregnant or breastfeeding women; 7. During the observation period (2 months), taking other analgesic medications (including non-steroidal anti-inflammatory drugs, opioid analgesics) not specified in this study protocol; 8. Herpes zoster lesions located outside the C2–C7, T1–L5 spinal nerve distribution areas, or coexisting with other painful conditions; 9. Inability to cooperate with assessments for any reason; 10. Aged 90 years or older;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The score of Herpes Zoster Disease Burden (HZ-BOI); | — |
Secondary
| Measure | Time frame |
|---|---|
| The VAS pain score after treatment;Sleep Quality Rating;Life Quality Rating;Anxiety Symptom Rating; | — |
Countries
China
Contacts
Public ContactTangjing
Affiliated Hospital of Guangdong Medical University
Outcome results
None listed